List of Excipients in Branded Drug MILRINONE LACTATE IN 5% DEXTROSE

Generic Drugs Containing MILRINONE LACTATE IN 5% DEXTROSE

Company	Ingredient	NDC	Excipient
Caplin Steriles Limited	milrinone lactate in 5% dextrose	65145-176	DEXTROSE MONOHYDRATE
Caplin Steriles Limited	milrinone lactate in 5% dextrose	65145-176	LACTIC ACID
Caplin Steriles Limited	milrinone lactate in 5% dextrose	65145-176	SODIUM HYDROXIDE
Caplin Steriles Limited	milrinone lactate in 5% dextrose	65145-176	WATER
Somerset Therapeutics LLC	milrinone lactate in 5% dextrose	70069-872	DEXTROSE MONOHYDRATE
Somerset Therapeutics LLC	milrinone lactate in 5% dextrose	70069-872	LACTIC ACID

What are the Most Frequently-Used Excipients in MILRINONE LACTATE IN 5% DEXTROSE?

# Of NDCs	Excipient
2	DEXTROSE MONOHYDRATE
2	LACTIC ACID
2	SODIUM HYDROXIDE
2	WATER

Milrinone Lactate in 5% Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 5, 2026

Milrinone lactate in 5% dextrose is an established intravenous inotrope formulation used for short-term treatment of acute decompensated heart failure. Its formulation profile is technically simple: milrinone lactate, dextrose, water for injection, and pH-adjusting agents. The principal commercial opportunities are ready-to-use premixed bags, differentiated concentrations, container systems, stability improvements, and hospital supply reliability rather than new-molecule exclusivity.

What is milrinone lactate in 5% dextrose?

Milrinone lactate is the lactate salt of milrinone, a phosphodiesterase-3 inhibitor administered by continuous intravenous infusion. It increases cardiac contractility and produces vasodilation. FDA labeling identifies milrinone lactate injection as a sterile solution for intravenous administration and describes products containing milrinone lactate in 5% dextrose injection [1].

Typical premixed strengths include:

Product configuration	Milrinone content	Fill volume	Nominal concentration
Ready-to-use bag	20 mg	100 mL	200 mcg/mL
Ready-to-use bag	40 mg	200 mL	200 mcg/mL
Ready-to-use bag	50 mg	250 mL	200 mcg/mL

The concentration most commonly associated with premixed milrinone in 5% dextrose is 200 mcg/mL. Hospital pharmacies may also dilute concentrated milrinone injection into 0.9% sodium chloride or 5% dextrose before administration, depending on the approved product and institutional protocol [1,2].

What excipients are used in milrinone lactate in 5% dextrose?

The core excipient system has four functional components:

Component	Function	Commercial relevance
Dextrose monohydrate in water	Isotonic vehicle and carbohydrate source	Enables ready-to-use infusion and standard hospital compatibility
Lactic acid or lactate counterion	Forms milrinone lactate salt	Supports solubility and injectable presentation
Sodium hydroxide	pH adjustment during manufacture	Controls chemical stability and tolerability
Water for injection	Sterile solvent	Provides parenteral-grade vehicle

The exact inactive-ingredient declaration depends on the manufacturer and presentation. U.S. labels generally identify dextrose, water for injection, and pH-adjusting ingredients. Some labels state that sodium hydroxide or lactic acid is used to adjust pH rather than identifying those materials as formulation components in the same manner as the primary vehicle [1,2].

The formulation is acidic. Product labeling commonly identifies a pH range near 3.2 to 4.0. This range supports solution stability but creates container-compatibility and extractables considerations for packaging developers.

Why is 5% dextrose commercially useful as the vehicle?

5% dextrose is a standard large-volume parenteral vehicle with established hospital familiarity. It offers several commercial advantages:

1. It eliminates bedside dilution for the premixed presentation.
2. It reduces compounding steps in intensive-care and cardiac-care units.
3. It supports standardized pump programming at a known concentration.
4. It uses existing hospital storage, infusion, and administration workflows.
5. It avoids the need to source a separate diluent for each dose.

The premix is particularly valuable where rapid initiation of therapy and reduction of pharmacy workload are priorities. The formulation does not require a novel excipient to create a differentiated product. Differentiation instead comes from presentation, stability, packaging, and supply performance.

What formulation patents protect milrinone lactate in 5% dextrose?

The core composition is unlikely to have meaningful current composition-of-matter protection. Milrinone was developed decades ago, and the original U.S. product, Primacor, received FDA approval in the 1980s. The relevant commercial products are generally generic or authorized-generic presentations rather than new chemical entities [3].

Patent protection should be analyzed across four categories:

Patent category	Relevance to milrinone lactate in 5% dextrose
Milrinone compound patents	Historical significance; generally expired
Lactate salt patents	Likely expired or commercially weak given product age
Basic injectable formulation patents	Generally expired or no longer a practical barrier
Container, process, or presentation patents	Potentially relevant for differentiated products
Method-of-use patents	Limited value where the indication and dosing are long established

The Orange Book should be reviewed for the specific reference-listed drug and current product identifiers. FDA’s Orange Book system identifies approved drugs and any applicable listed patents or exclusivity information, but the existence of an approved milrinone product does not establish that a live patent blocks a new generic or premixed presentation [4].

For a new applicant, the key intellectual-property risk is more likely to arise from a specific device, container closure, manufacturing process, or proprietary stability package than from milrinone itself.

When does milrinone lose exclusivity?

Milrinone’s primary pharmaceutical exclusivity expired long ago. The original U.S. approval predates the modern five-year NCE exclusivity framework created by the Hatch-Waxman Amendments. Current market access is therefore driven by abbreviated new drug applications, manufacturing capacity, FDA quality requirements, and procurement contracts rather than by remaining NCE exclusivity [3,5].

The practical exclusivity timeline is:

Milestone	Commercial implication
Original Primacor approval	Established the branded reference product
Expiration of historical compound and formulation rights	Opened the market to generic manufacturers
Generic approvals	Shifted competition toward price, supply, and presentation
Current market	Primarily a mature injectable-generic opportunity

No biosimilar pathway applies. Milrinone is a small molecule, not a biologic. FDA approval is pursued through an ANDA or, depending on the product’s differences, a 505(b)(2) NDA pathway.

What is the FDA regulatory status of milrinone lactate in 5% dextrose?

Milrinone lactate is an FDA-approved prescription intravenous drug. The product is used for short-term management of acute decompensated heart failure, including treatment in monitored hospital settings. FDA-approved labeling includes dosing by loading dose and continuous infusion, with dose adjustment considerations for renal impairment [1].

A premixed solution in 5% dextrose can potentially be approved through an ANDA when it demonstrates pharmaceutical equivalence and bioequivalence or an applicable waiver to the reference product. Differences in concentration, container, dosage form, or labeling can affect the appropriate regulatory pathway.

Relevant regulatory issues include:

• Sterility assurance and aseptic processing.
• Particulate control.
• Container-closure integrity.
• Extractables and leachables.
• Stability through the labeled shelf life.
• Compatibility with infusion devices and administration sets.
• Light sensitivity and storage conditions.
• Labeling for premixed versus concentrated product.
• Control of dextrose concentration and osmolality.
• In-use stability after bag entry or connection to an administration set.

FDA’s guidance on sterile drug products and ICH stability principles provides the principal framework for development and lifecycle management [5,6].

What formulation opportunities exist for milrinone premixed bags?

Ready-to-use hospital bags

The strongest near-term opportunity is a standard 200 mcg/mL premixed bag in multiple fill volumes. Hospitals value products that reduce preparation time and dosing variability. A supplier can offer 100 mL, 200 mL, and 250 mL presentations to align with different infusion durations and inventory policies.

High-concentration presentations

A higher concentration could reduce fluid load for patients requiring prolonged infusion or fluid restriction. A product developer would need to address:

• Local tolerability and infusion-site considerations.
• Pump accuracy at lower infusion rates.
• Stability at higher milrinone concentration.
• Labeling separation from the standard 200 mcg/mL product.
• Medication-error risk from concentration interchangeability.

A high-concentration product could follow an ANDA or 505(b)(2) pathway depending on the reference product and formulation differences.

Dual-source packaging

Offering the same formulation in both polymer bags and glass or rigid containers can support different hospital purchasing requirements. Polymer bags provide lower weight and easier handling. Rigid containers may appeal to institutions with established automated compounding or storage systems.

Improved overwrap and oxygen control

The commercial value of oxygen-control measures depends on demonstrated impact on degradation, color, particulates, or shelf life. Possible technologies include:

• Low-permeability multilayer bags.
• Improved overwraps.
• Nitrogen headspace control where applicable.
• Enhanced light protection.
• Low-sorbing administration components.

These measures are most valuable when they extend shelf life, reduce excursions, or support broader distribution.

How strong is the patent estate for milrinone lactate in 5% dextrose?

The underlying patent estate is weak from a lifecycle perspective because the active ingredient and standard injectable use are mature. The defensible IP opportunity lies in narrow technical claims.

Potential claim areas include:

Claim area	Potential strength
New milrinone chemical entity	Very low practical value due to age of compound
Milrinone lactate salt	Low unless a genuinely new crystalline or stability form exists
Milrinone in 5% dextrose	Low for a conventional composition
Specific concentration and shelf life	Moderate if supported by unexpected stability data
Container and closure system	Moderate, but often vulnerable to design-around
Manufacturing process	Moderate if process-specific and difficult to replicate
Combination with specialized infusion device	Moderate to high if device claims are narrow and commercially relevant
New dosing method	Potentially moderate, subject to prior-art and obviousness analysis

A patent strategy based solely on “milrinone lactate in 5% dextrose” would likely be difficult to sustain against prior-art challenges. A stronger strategy would combine a defined concentration, container system, stability profile, and manufacturing control that produces a measurable technical advantage.

Which companies are challenging or supplying milrinone products?

Milrinone has historically been supplied by the originator associated with Primacor and by multiple generic injectable manufacturers. Current suppliers can change because of discontinuations, acquisitions, shortage conditions, and contract-manufacturing arrangements. FDA’s Drugs@FDA database, the Orange Book, and current DailyMed labeling are the appropriate sources for identifying active applicants, label holders, and marketed presentations [2-4].

Competition is based on:

• Unit price.
• Contract terms with group purchasing organizations.
• Hospital shortage performance.
• Shelf life.
• Bag and vial configurations.
• Manufacturing redundancy.
• Regulatory compliance history.
• Ability to supply critical-care products continuously.

The market is not driven by consumer branding. Procurement reliability and approved presentation are more important than promotional differentiation.

What generic entry risks exist?

The main risks to a new entrant are operational rather than patent-based.

Manufacturing and quality risk

Sterile injectable manufacturing requires validated aseptic processes, environmental controls, container-closure testing, and reliable supply of pharmaceutical-grade dextrose and packaging components. A supplier with a single manufacturing site faces higher disruption risk.

Shortage and allocation risk

Milrinone is used in acute-care settings, where hospitals may maintain limited alternatives. Manufacturing interruptions can generate rapid demand shifts. A new entrant with redundant production and inventory capacity can gain share during supply interruptions.

Labeling and medication-error risk

Multiple concentrations can create selection errors. A differentiated product must use clear concentration labeling, barcode compatibility, and packaging that distinguishes standard and high-concentration presentations.

Compatibility risk

The formulation must be evaluated with commonly used infusion systems, filters, tubing, and pumps. Adsorption, precipitation, particulate formation, and pH-related incompatibility can reduce hospital adoption even where the product meets release specifications.

How does milrinone compare with competing inotropes?

Milrinone competes clinically with dobutamine and, in some settings, other vasoactive therapies. The products differ in pharmacology, formulation, dosing, and supply characteristics.

Attribute	Milrinone lactate	Dobutamine
Pharmacology	PDE-3 inhibition	Beta-adrenergic agonism
Typical use	Short-term acute heart-failure support	Short-term inotropic support
Common vehicle	5% dextrose or compatible diluent	Frequently supplied in dextrose-based solutions
Key formulation opportunity	Ready-to-use premix and concentration options	Broad generic and premix competition
Main commercial differentiator	Supply reliability and standardized bags	Price, availability, and hospital contracts

Milrinone may be selected where clinicians seek an inodilator effect or where beta-adrenergic responsiveness is limited. The product remains a hospital-use medicine, so formulation convenience can influence purchasing even when clinical differentiation is modest.

What licensing and partnering opportunities exist?

Licensing value is more likely to arise from manufacturing and distribution capabilities than from the milrinone molecule. Potential structures include:

• Contract manufacturing of sterile premixed bags.
• Regional marketing rights.
• Authorized-generic arrangements.
• Hospital and group-purchasing supply agreements.
• Co-development of a high-concentration product.
• Technology licensing for low-sorption or extended-stability packaging.
• Portfolio bundling with other critical-care injectables.

A partner with an established ANDA, validated sterile facility, and hospital distribution network may be more valuable than a partner holding narrow formulation patents. Contract terms should address shortages, minimum purchase volumes, quality events, recalls, regulatory changes, and supply-continuity obligations.

What revenue exposure does milrinone create?

Milrinone is a mature generic injectable, so absolute revenue is generally constrained by low unit pricing and hospital procurement pressure. Revenue exposure is concentrated in product availability rather than consumer demand.

The largest commercial variables are:

1. Annual hospital volume.
2. Bag-versus-vial mix.
3. Contract pricing.
4. Manufacturing yield and batch size.
5. Shelf life and inventory write-offs.
6. Shortage-driven market share.
7. Geographic registration and distribution.
8. Portfolio leverage with other intensive-care injectables.

A ready-to-use bag can command a commercial premium over a concentrated vial when it reduces pharmacy preparation and administration burden. That premium must offset the additional cost of large-volume parenteral manufacturing, packaging, shipping, and inventory.

What geographic coverage is available?

The formulation has potential across regulated hospital markets that accept dextrose-based large-volume parenterals. Expansion requires country-specific review of:

• Registered strengths and bag sizes.
• Dextrose labeling requirements.
• Local pharmacopoeial standards.
• Import and serialization rules.
• Hospital tender procedures.
• Cold-chain or controlled-storage requirements.
• Local reference-product expectations.
• Language and medication-safety labeling.

The United States, European Union, Canada, Australia, and selected emerging markets may each require different regulatory evidence. Local demand is strongest where intensive-care infrastructure supports continuous infusion and hospitals purchase standardized premixed products.

Key Takeaways

• Milrinone lactate in 5% dextrose is a mature, generic intravenous formulation.
• The standard commercial concentration is approximately 200 mcg/mL.
• The principal excipients are dextrose, water for injection, and pH-adjusting materials associated with the lactate salt system.
• Core compound and conventional formulation patents are unlikely to create a meaningful current barrier.
• The best commercial opportunities are ready-to-use bags, multiple fill volumes, high-concentration products, and improved stability or packaging.
• Product differentiation depends on sterile manufacturing, shelf life, compatibility, supply reliability, and hospital procurement value.
• Milrinone is a small molecule and has no biosimilar pathway.
• An ANDA is potentially appropriate for a pharmaceutically equivalent product; a 505(b)(2) pathway may be relevant for meaningful formulation or presentation differences.
• Licensing value is concentrated in manufacturing capacity, distribution, and hospital contracts rather than molecule ownership.
• The strongest defensible IP would cover a specific container, stability profile, manufacturing process, or integrated delivery system.

FAQs

Is milrinone lactate in 5% dextrose a premixed product?

Yes. Premixed products are supplied at a defined concentration, commonly 200 mcg/mL, in ready-to-use infusion bags. Other milrinone products may be supplied as concentrated injections requiring dilution.

Can milrinone lactate be reformulated in normal saline?

Some labeled milrinone products permit dilution in compatible infusion solutions, including 0.9% sodium chloride. The permitted diluents and stability conditions must be taken from the specific product label rather than assumed across manufacturers [1,2].

Does milrinone lactate have biosimilar competition?

No. Milrinone is a small-molecule drug. Competitors use generic-drug approval pathways rather than the FDA biosimilar pathway.

Can a new company patent milrinone in 5% dextrose?

A conventional composition is unlikely to provide strong new patent protection because of extensive prior art. Patentability is more plausible for a technically specific concentration, container system, manufacturing process, or stability result supported by comparative data.

What is the most attractive commercial presentation?

A ready-to-use 200 mcg/mL bag in 100 mL, 200 mL, or 250 mL formats is the most straightforward commercial presentation. A high-concentration bag may offer greater differentiation but carries higher regulatory, compatibility, and medication-safety requirements.

References

1. U.S. Food and Drug Administration. (n.d.). Milrinone lactate injection prescribing information. FDA-approved product labeling.

2. National Library of Medicine. (n.d.). DailyMed: Milrinone lactate injection. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2015). ANDA submissions: Content and format of an ANDA. Center for Drug Evaluation and Research.

6. International Council for Harmonisation. (2003). ICH Q1A(R2): Stability testing of new drug substances and products.